No Data
No Data
Immuron Posts 253% Jump in Travelan Sales in Fiscal Q4; Shares Rise 10%
Immuron (ASX:IMC) reported a 253% jump to AU$1.3 million in sales of over-the-counter immune supplement Travelan for the fourth quarter ended June 30.The surge was supported by on-year jumps of 200%
Immuron Files Pre-Investigational New Drug Application With FDA for IMM-529
Biopharmaceutical company Immuron (ASX:IMC) filed a pre-investigational new drug application with the US Food and Drug Administration for IMM-529, a candidate for the treatment of gastrointestinal dis
Immuron Says Jeannie Joughin Was Appointed to Board >IMRN
Immuron Says Jeannie Joughin Was Appointed to Board >IMRN
Immuron Says Roger Aston Has Resigned From Board of Directors
Immuron Says Roger Aston Has Resigned From Board of Directors
Immuron's Global Sales Climb 51% in March Quarter; Shares Surge 18%
Immuron (ASX:IMC) saw a 51% surge in global sales in the March quarter compared with the prior comparative period, driven by a strong performance of its Travelan product in Australia, according to a W
ADRs Close Lower, Immuron Ltd. Declines 17.1%
This article was automatically generated by Dow Jones Newswires using technology from Automated Insights. International stocks trading in New York closed lower on Monday, as the S&P/BNY Mellon index
No Data